Cargando…
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623999/ https://www.ncbi.nlm.nih.gov/pubmed/36316695 http://dx.doi.org/10.1186/s13045-022-01369-2 |
| _version_ | 1784822133643280384 |
|---|---|
| author | Jiang, Qian Li, Zongru Qin, Yazhen Li, Weiming Xu, Na Liu, Bingcheng Zhang, Yanli Meng, Li Zhu, Huanling Du, Xin Chen, Suning Liang, Yang Hu, Yu Liu, Xiaoli Song, Yongping Men, Lichuang Chen, Zi Niu, Qian Wang, Hengbang Lu, Ming Yang, Dajun Zhai, Yifan Huang, Xiaojun |
| author_facet | Jiang, Qian Li, Zongru Qin, Yazhen Li, Weiming Xu, Na Liu, Bingcheng Zhang, Yanli Meng, Li Zhu, Huanling Du, Xin Chen, Suning Liang, Yang Hu, Yu Liu, Xiaoli Song, Yongping Men, Lichuang Chen, Zi Niu, Qian Wang, Hengbang Lu, Ming Yang, Dajun Zhai, Yifan Huang, Xiaojun |
| author_sort | Jiang, Qian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9623999 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96239992022-11-02 Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial Jiang, Qian Li, Zongru Qin, Yazhen Li, Weiming Xu, Na Liu, Bingcheng Zhang, Yanli Meng, Li Zhu, Huanling Du, Xin Chen, Suning Liang, Yang Hu, Yu Liu, Xiaoli Song, Yongping Men, Lichuang Chen, Zi Niu, Qian Wang, Hengbang Lu, Ming Yang, Dajun Zhai, Yifan Huang, Xiaojun J Hematol Oncol Correction BioMed Central 2022-10-31 /pmc/articles/PMC9623999/ /pubmed/36316695 http://dx.doi.org/10.1186/s13045-022-01369-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Jiang, Qian Li, Zongru Qin, Yazhen Li, Weiming Xu, Na Liu, Bingcheng Zhang, Yanli Meng, Li Zhu, Huanling Du, Xin Chen, Suning Liang, Yang Hu, Yu Liu, Xiaoli Song, Yongping Men, Lichuang Chen, Zi Niu, Qian Wang, Hengbang Lu, Ming Yang, Dajun Zhai, Yifan Huang, Xiaojun Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| title | Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| title_full | Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| title_fullStr | Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| title_full_unstemmed | Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| title_short | Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| title_sort | correction: olverembatinib (hqp1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with t315i-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623999/ https://www.ncbi.nlm.nih.gov/pubmed/36316695 http://dx.doi.org/10.1186/s13045-022-01369-2 |
| work_keys_str_mv | AT jiangqian correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT lizongru correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT qinyazhen correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT liweiming correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT xuna correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT liubingcheng correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT zhangyanli correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT mengli correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT zhuhuanling correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT duxin correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT chensuning correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT liangyang correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT huyu correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT liuxiaoli correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT songyongping correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT menlichuang correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT chenzi correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT niuqian correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT wanghengbang correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT luming correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT yangdajun correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT zhaiyifan correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial AT huangxiaojun correctionolverembatinibhqp1351awelltoleratedandeffectivetyrosinekinaseinhibitorforpatientswitht315imutatedchronicmyeloidleukemiaresultsofanopenlabelmulticenterphase12trial |